Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Borgenhaugen – page 2

89 clinical trials in Borgenhaugen, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Borgenhaugen at a glance
89
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

89 trials in Borgenhaugen

Open in trial search

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Major depression+1

Recruiting

A study on ketamine maintenance treatment for patients with treatment-resistant major depression disorder

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ketamine Hydrochloride
  • Sponsor:Ostfold Hospital Trust

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Region Midtjylland

Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Sepsis

Recruiting

Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Akershus University Hospital

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study on the Safety and Effectiveness of Pirtobrutinib for Adults with Immune Thrombocytopenia

Investigational
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.